<DOC>
	<DOC>NCT00291759</DOC>
	<brief_summary>The purpose of this study is to assess the difference in event-free survival between postmenopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastrozole and those who continued to receive tamoxifen.</brief_summary>
	<brief_title>ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Invasive mammary carcinoma after radical treatment, without prior chemo/hormone/radiation therapy. At least 6 lymph nodes examined. Good or intermediate tumour differentiation. &lt;6 weeks before start of adjuvant therapy. Oestrogen or Progesterone positive Premenopausal. Preoperative hormonal/antihormonal/radiation/cytoxic chemo. Second malignant tumour/status post second malignant tumour. Insitu/T4 carcinoma. Age &gt;80 years. World Health Organisation performance index &gt;3. Serious accompanying diseases</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>